Table 6.

Univariable and multivariable analyses of predictors of clinical remission.

	Week 52 OR (95%CI); p-value*	Week 104 OR (95%CI); p-value*	Week 52 OR (95%CI); p-value*	Week 104 OR (95%CI); p-value*
Sex Female (ref. male)	0.58 (0.20–1.69); .32	0.71 (0.19–2.61); .61
HBI score at baseline	0.74 (0.62–0.89); < .001	0.80 (0.66–0.97); .02	0.64 (0.49–0.84); .002	0.72 (0.54–0.96); .02
Age at diagnosis**
A1	Ref	Ref
A2	7.00 (0.72–68.15); .09	0.67 (0.06–7.18); .74
A3	1.60 (0.10–24.70); .74	0.33 (0.02–5.33); .44
At inclusion	1.01 (0.98–1.05); .72	0.98 (0.94–1.03); .46
Location**
Ileal, L1	Ref	Ref
Colonic. L2	1.60 (0.30–8.49); .58	1.00 (0.16–6.25) 1.00
Ileocolonic, L3	0.49 (0.14–1.70); .26	0.88 (0.20–3.85); .86
Behavior**
Inflammatory, B1	Ref	Ref
Stricturing, B2	0.60 (0.16–2.31); .46	0.37 (0.06–2.19); .27
Penetrating, B3	0.56 (0.10–3.25); .51	0.20 (0.02–2.39); .20
Perianal, p	0.69 (0.13–3.84); .68	0.15 (0.02–1.26); .08
EIM at baseline	0.14 (0.03–0.79); .03	0.12 (0.01–1.34); .09	0.22 (0.02–2.12); .19	0.08 (0.004–1.56); .10
Previous surgery	0.50 (0.17–1.45); .20	0.27 (0.07–1.07); .06
Medication at baseline
Corticosteroids	0.47 (0.12–1.89); .29	0.67 (0.13–3.47); .63
Immunomodulators	0.51 (0.15–1.74); .28	0.43 (0.10–1.84); .26
Termination of last biological drug
aTNF or anti-integrin naïve	Ref	Ref
Lack of response	0.65 (0.05–7.69); .73	2.36 (0.14–41.27); .56
Adverse drug event or other reason	0.38 (0.02–6.35); .50	0.33 (0.01–11.94); .55

aTNF = anti-tumor necrosis factor; EIM = extra-intestinal manifestation; HBI = Harvey-Bradshaw Index

* p-values of < 0.05 were considered statistically significant and are given in italics

**According to the Montreal Classification of Disease